Our Faculty

Walter M. Stadler, MD

  • Fred C. Buffett Professor of Medicine
    Committee on Cancer Biology
    Associate Dean of Clinical Science Research, Clinical Trials
  • Clinical Interests: Bladder Cancer, Kidney Cancer, Prostate Cancer, Renal Cancer, Testicular Cancer, Urologic Cancers
  • Websites: Research Network Profile
  • Graduate Programs: Cancer Biology, UChicago Biosciences

PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial.
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nat Commun. 2024 Dec 30; 15(1):10743.
PMID: 39737899

Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting. Urol Oncol. 2024 Nov 04.
PMID: 39500687

Feasibility of structuring electronic health record data to facilitate real-world data research: ICAREdata methods applied to multicenter cancer clinical trials.
Feasibility of structuring electronic health record data to facilitate real-world data research: ICAREdata methods applied to multicenter cancer clinical trials. Cancer. 2025 Jan 01; 131(1):e35528.
PMID: 39192753

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024 Aug 22; 391(8):710-721.
PMID: 39167807

There Is More to Length of Survival Than Survival: Endpoints in Oncology Trials.
There Is More to Length of Survival Than Survival: Endpoints in Oncology Trials. Clin Cancer Res. 2024 Aug 01; 30(15):3098-3099.
PMID: 38767553

PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness. Prostate. 2024 Feb; 84(3):292-302.
PMID: 37964482

Enrollment Barriers for Molecular Targeted Trials.
Enrollment Barriers for Molecular Targeted Trials. JAMA Oncol. 2023 06 01; 9(6):863-864.
PMID: 37022722

Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022 10 01; 8(10):1411-1418.
PMID: 36048457

A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer.
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2022 12; 20(6):575-580.
PMID: 36210299

Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors.
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors. Clin Genitourin Cancer. 2022 12; 20(6):510-514.
PMID: 35869002

View All Publications